Sign In
19 Dec 2019 11:59
Block Listing Application
London, UK - 19 December 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,500,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.
The New Ordinary Shares represent an increase on the Company's current Block Listing facility admitted on 02 July 2018 (the 'Block Listing'). It is expected that the admission of the New Ordinary Shares will become effective on 02 January 2020.
Ordinary Shares from the Block Listing will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Long Term Incentive Plan.
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').
The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Richard Barfield (Chief Financial Officer) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield/Huw Jeremy (Nominated Adviser) | |
James Black (Broker) | |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Sue Stuart Matthew Neal/Olivia Manser | ergomed@consilium-comms.com |
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 |
Anne Hennecke |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
Follow the stocks
